Clinical Trials
14 trialsNCT01613144 2022-02-25
EVOLVE
Alphatec Spine, Inc.
Completed
NCT00980174 2018-10-17
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
Amgen
Phase 3 Completed
NCT00211211 2017-12-08
FREE Study - Fracture Reduction Evaluation
Medtronic Spinal and Biologics
Phase 4 Completed
NCT00063609 2017-09-13
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
Novartis
Phase 4 Completed
NCT00925600 2017-05-30
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
Amgen
Phase 3 Completed
NCT01871519 2017-03-29
EVOLVE
Medtronic Spinal and Biologics
Phase NA Completed
NCT00172055 2017-03-06
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
Novartis
Phase 3 Completed
NCT00050011 2014-03-21
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Novartis
Phase 3 Completed
NCT00129142 2013-11-15
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
GTx
Phase 3 Completed
NCT00332709 2011-11-16
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Novartis
Phase 3 Completed
NCT00082277 2011-01-26
SABRE
AstraZeneca
Phase 4 Completed
NCT00816452 2010-11-03
InoPro
Sanofi
Completed
NCT01025479 2010-06-30
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
AstraZeneca
Completed
NCT00767585 2009-07-03
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
AstraZeneca
Completed